Published Research and Presentations

Overall survival (OS) Results of a Phase III Randomized Trial of Standard of Care Therapy with or without enzalutamide for a Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP –led International Co-operative Group Trial

ENZAMET

MOGA ASM

16/08/2019

Professor Ian D. Davies

Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial

ENZAMET

ASCO Plenary

02/06/2019

Professor Christopher J. Sweeney, MMBS

“Discrepancies in registry Coding for Penile cancer” and “The significance of demographic location in survival outcomes”.

Other

USANZ ASM

14/02/2019

Dr Simeon Ngweso – Villas Marshall Prize Winner, Penile cancer in Western Australia

TheraP: A randomized phase II trial of [177Lu]-PSMA-617 theranostic versus cabazitaxel in progressive metastatic castration-resistant prostate cancer.

TheraP

ASCO GU

14/02/2019

An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours: P3BEP (ANZUP 1302)

P3BEP

ASCO GU

14/02/2019

Crossing the paediatric and adult hospital divide: An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours

P3BEP

3rd AYA congress

04/12/2018

Walker et al.

An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor risk metastatic germ cell tumours: P3BEP (ANZUP 1302)

P3BEP

American Society of Clinical Oncology – Genitourinary Symposium

01/06/2018

Namrata Nayar, et al.

Abstract #219679 CCTG BL12: Randomized phase II trial comparing nab-paclitaxel (Nab-P) to paclitaxel (P) in patients (pts) with advanced urothelial cancer progressing on or after a platinum containing regimen

BL12

American Society of Clinical Oncology (ASCO) Annual Meeting

01/06/2018

Srikala S Sridhar et al.

Randomised phase 3 trial of enzlautamide in androgen deprivation therapy (ADT) with radiation therapy for high risk, clinically localised prostate cancer: ENZARAD (ANZUP 1303)

ENZARAD

American Society of Clinical Oncology – Genitourinary Cancers, San Francisco

14/02/2018

S. Williams et al.

P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs)

P3BEP

Clinical Oncology Society of Australia

13/11/2017

Nayar N, Lawrence N, Stockler M, Martin A, Yip S, Wong N, Yeung A, Friedlander M, Mazhar D, Pashankar F, Quinn D, Walker R, Winstanley M, Hanning F, Weickhardt A, Stevanovic A, Davis I, Toner G, Grimison P.